JANSSEN GLOBAL SERVICES LLC

In News

Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer - Johnson & Johnson

Johnson & Johnson - Jul 17, 2025

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma - PR Newswire

PR Newswire - May 20, 2025

Analgesics Market | Global Market Analysis Report - 2035 - Fact.MR

Fact.MR - Nov 20, 2025

J&J Ends Trade Secrets Suit Against Now Deceased Ex-Exec - Law360

Law360 - Apr 22, 2025

Christopher Janssen | Fairness and Solvency Opinions - Kroll

Kroll - Jun 28, 2025

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer - Johnson & Johnson

Johnson & Johnson - Mar 26, 2025

Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival - Wiley

Wiley - Sep 10, 2025

Janssen to stop clinical development of pimodivir for influenza - Clinical Trials Arena

Clinical Trials Arena - Sep 03, 2020

What Does the Phase III ‘IMROZ’ Study Mean for Patients with Multiple Myeloma? An Interview with the Co-authors - European Medical Journal

European Medical Journal - Jul 15, 2024

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database - Nature

Nature - Dec 05, 2024

Cynthia Sung Receives Johnson & Johnson Women in STEM2D Scholars Award - University of Pennsylvania

University of Pennsylvania - Nov 12, 2025

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus - Investing News Network

Investing News Network - Mar 03, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment